title: Oral 9-cis retinoic acid (Alitretinoin) in the treatment of myelodysplastic syndromes: results from a pilot study.
abstract: A multicenter phase II study was initiated to investigate the efficacy, toxicity and tolerability of an oral regimen of 9-cis retinoic acid (9CRA) as a differentiation-inducing agent stimulating both retinoic acid receptor (RAR) and retinoic X receptor (RXR). Thirty patients with myelodysplastic syndromes (MDS) were enrolled into the study. The MDS subtypes were distributed as follows: 14 refractory anaemia (RA), four refractory anaemia with ringed sideroblasts (RARS), and 12 refractory anaemia with excess blasts (RAEB). The age ranged from 40 to 81 years (median 70). None of these had previously received treatment for MDS other than supportive therapy. 9CRA (Alitretinoin capsules, kindly provided by Allergan-Ligand Retinoid Therapeutics) was given daily at 60 mg/m2 p.o. for 1 week, followed by an intra-patient escalation to 100 mg/m2 during the second week, up to a maximum of 140 mg/m2. The planned treatment duration was 48 weeks. Twenty-five were available for assessment. One patient (4%) with RA achieved complete hematological remission. Four (16%), two with RA, two with RAEB, had minor responses resulting in decreased transfusion requirements or increased neutrophils. Thus, the overall response rate was 20% in evaluable patients with MDS and 17% in the study group on an intention-to-treat basis. The most frequent side-effects included headache (77%), dry skin (57%), arthralgias (30%), and rash (23%). In conclusion, although modest responses were noted in this study, the treatment tolerability was suboptimal. It is conceivable that a lower dosage schedule may be efficacious and better tolerated so enabling prolonged exposure which may be required to induce a differentiation effect.
authors.affiliation: Department of Hematology/Oncology, University of Frankfurt/Main, Germany.
authors.forename: W K
authors.initials: WK
authors.lastname: Hofmann
authors.forename: W J
authors.initials: WJ
authors.lastname: Kell
authors.forename: P
authors.initials: P
authors.lastname: Fenaux
authors.forename: S
authors.initials: S
authors.lastname: Castaigne
authors.forename: A
authors.initials: A
authors.lastname: Ganser
authors.forename: C
authors.initials: C
authors.lastname: Chomienne
authors.forename: R
authors.initials: R
authors.lastname: Burnett
authors.forename: C
authors.initials: C
authors.lastname: Kowal
authors.forename: D
authors.initials: D
authors.lastname: Hoelzer
authors.forename: A K
authors.initials: AK
authors.lastname: Burnett
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000077556:Alitretinoin; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001803:Blood Transfusion; D005260:Female; D006410:Hematopoiesis; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D010865:Pilot Projects; D016896:Treatment Outcome; D014212:Tretinoin / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D000077556:Alitretinoin; D014212:Tretinoin